Compare PICS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PICS | PGEN |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | PICS | PGEN |
|---|---|---|
| Price | $13.08 | $4.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $22.00 | $8.33 |
| AVG Volume (30 Days) | 702.6K | ★ 5.4M |
| Earning Date | 05-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $29.68 | $1,115.92 |
| Revenue Next Year | $39.06 | $81.04 |
| P/E Ratio | $29.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $1.23 |
| 52 Week High | $18.49 | $5.47 |
| Indicator | PICS | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 53.07 |
| Support Level | $10.09 | $3.31 |
| Resistance Level | $15.33 | $4.44 |
| Average True Range (ATR) | 0.79 | 0.34 |
| MACD | 0.37 | 0.07 |
| Stochastic Oscillator | 89.54 | 71.43 |
PicS NV is a digital payments company. The company operates a peer-to-peer (P2P) transfer platform that enables individuals to send money via mobile devices. It provides digital wallets, instant payments (Pix), P2P transfers, credit cards, loans, investments, insurance, and SMB payment solutions. The company has four reportable segments: Consumer Banking, Small and Medium-Sized Businesses, Audiences and Ecosystem Integration, and Institutional. The majority of the company's revenue is derived from the Consumer Banking segment, which generates revenue from various transaction activities occurring in the digital wallet, such as Pix, peer-to-peer (P2P) transfers, and bill payments.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.